The Proventys Board of Directors includes:
G. Steven Burrill
Chief Executive Officer, Burrill & Company
Steven Burrill has been involved in the growth of the biotechnology industry for over 35 years. He currently serves as Chairman of the Boards of Icoria, Pharmasset, and Pyxis Genomics; Chairman of the San Francisco Mayor's Biotechnology Advisory Council; and is a member of the Boards of Directors for Catalyst Biosciences, DepoMed, Galapagos Genomics, Targacept, and Third Wave Technologies. Prior to founding Burrill & Company in 1994, Mr. Burrill spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the industries of biotechnology, life sciences, high technology, and manufacturing worldwide. Mr. Burrill is a founder of the Foundation for the National Medals of Science and Technology and currently serves on its Board of Directors. He also serves on the Boards of Directors for the Bay Area Science Infrastructure Consortium, BayBio, California Healthcare Institute, Exploratorium, Kellogg Center for Biotechnology, and University of California - San Francisco Foundation.
David M. Lawrence, MD
Former CEO and Chairman of the Boards of Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals
David Lawrence is former CEO and Chairman of the Boards of Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals, retiring in 2002. Dr. Lawrence began his career with Kaiser Permanente with the Northwest Permanente Medical Group in 1981, and held the positions of CEO and Chairman. He serves on the Boards of Agilent Technologies, Pacific Gas and Electric Corporation, Raffles Medical Group of Singapore, McKesson Corporation, and the RAND Health Advisory Board, among others. He also serves in advisory roles to the biotechnology industry. Prior to joining Kaiser Permanente, Dr. Lawrence worked in academic medicine, public health, and international health. He is board certified in general preventive medicine, attended the Advanced Management Program at Harvard, and is a member of the Alpha Omega Alpha Society and the Institute of Medicine.
Marc Owen
Executive Vice
President, Corporate Strategy and Business Development McKesson Corporation
Marc Owen is
Executive Vice President of Corporate Strategy and Business Development. He is
responsible for leading all strategy development across the company as well as
all merger and acquisition activity. In addition, he has operating responsibility
for McKesson’s businesses in Mexico
and Asia-Pacific.
Under Owen’s
leadership, McKesson has pursued a strategy based on focused business unit
goals complemented by initiatives that cut across the company. He has played
key roles in defining the company’s payor strategy, leading the company’s
efforts in electronic prescribing, and expanding its international presence. On
the merger and acquisition front he has led the company’s acquisitions of ALI
Technologies (medical imaging), Moore Medical (medical supplies), SI/Baker (pharmacy
automation), and Sky Pharmaceuticals (packaging). In total he has overseen
about 20 acquisitions over the last four years.
Owen joined
McKesson in 2001 as Senior Vice President of Corporate Strategy and Business
Development. Prior to joining McKesson he was CEO of MindCrossing. He spent 12
years at McKinsey and Company and was elected a Senior Partner (Director) in
1998. During his time at McKinsey he served clients in the pharmaceutical and
technology industries. He was a founding partner of McKinsey’s office in Palo Alto and led the Western U.S.
for McKinsey’s Business Technology Office. He was recognized by Consulting
Magazine as one of the top consultants in the area of business and technology.
Owen grew up
in Wales and was educated at
Oxford University. He was the youngest law
faculty member at Cambridge
University and
subsequently obtained his MBA from Stanford in 1987. He currently lives in Silicon Valley and is married with two teenage daughters.
Ralph Snyderman, MD, Chairman of the Board
Dr. Ralph Snyderman, founder of Proventys, Inc., is also Chancellor Emeritus, Duke University and James B. Duke Professor of Medicine at Duke University. He served as Duke�s Chancellor for Health Affairs and Dean of the School of Medicine from 1989 to July 2004. During his tenure, the medical school and hospital ranked among the nation�s best. Dr. Snyderman oversaw the development of the Duke University Health System, one of the nation�s most successful integrated academic health systems, and served as its first President and Chief Executive Officer. He has played a leading role in the conception and development of Prospective Care, a novel approach to personalized health and an evolving model of national health care delivery. Dr. Snyderman is called upon by Congress, the Institute of Medicine, the National Institutes of Health, and national policy makers to contribute to the debate on health care reform. He plays a prominent role in the leadership of national organizations such as the Association of American Physicians over which he presided in 2003-2004, the Institute of Medicine, of which he was a counselor, and the Association of American Medical Colleges (AAMC) which he chaired in 2001-2002. He is a member of the Institute of Medicine and the American Academy of Arts & Sciences.
